The role of prolactin/vasoinhibins in cardiovascular diseases
Animal Models and Experimental Medicine · 2023-04 · 6 (2) · 81-91
DOI: 10.1002/ame2.12264 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Animal Models and Experimental Medicine, online erschienen am 03.08.2022. Verfasst von Hui Zhao und 10 weiteren Autor:innen. Beteiligte Einrichtung: School of Materials and Chemistry & Institute of Bismuth and Rhenium, University of Shanghai for Science and Technology, Shanghai, China. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Prolactin. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 93 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Shanghai, Health and Family Planning Commission of Sichuan Province.
Abstract (Originalsprache)
Prolactin (PRL) is a polypeptide hormone that is mainly synthesized and secreted by the lactotroph cells of the pituitary. There are two main isoforms of PRL: 23‐kDa PRL (named full‐length PRL) and vasoinhibins (including 5.6–18 kDa fragments). Both act as circulating hormones and cytokines to stimulate or inhibit vascular formation at different stages and neovascularization, including endothelial cell proliferation and migration, protease production, and apoptosis. However, their effects on vascular function and cardiovascular diseases are different or even contrary. In addition to the structure, secretion regulation, and signal transduction of PRL/vasoinhibins, this review focuses on the pathological mechanism and clinical significance of PRL/vasoinhibins in cardiovascular diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Materials and Chemistry & Institute of Bismuth and Rhenium, University of Shanghai for Science and Technology, Shanghai, China.
- Department of Cardio-Pulmonary Circulation, School of Medicine, Shanghai Pulmonary Hospital, Tongji University, Shanghai, China.
- Respiratory Medicine, Dongchuan District People's Hospital, Kunming, China.
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Shanghai
- Health and Family Planning Commission of Sichuan Province
- Shanghai Pulmonary Hospital
Zitieren
APA
Zhao, H., Gong, S., Shi, Y., Luo, C., Qiu, H., He, J., Sun, Y., Huang, Y., Wang, S., Miao, Y., & Wu, W. (2023). The role of prolactin/vasoinhibins in cardiovascular diseases. Animal Models and Experimental Medicine, 6(2), 81-91. https://doi.org/10.1002/ame2.12264
Vancouver
Zhao H, Gong S, Shi Y, Luo C, Qiu H, He J, et al. The role of prolactin/vasoinhibins in cardiovascular diseases. Animal Models and Experimental Medicine. 2023;6(2):81-91. doi:10.1002/ame2.12264
BibTeX
@article{Zhao2023,
author = {Zhao, Hui and Gong, Sugang and Shi, Yongcong and Luo, Cijun and Qiu, Hongling and He, Jing and Sun, Yuanyuan and Huang, Yuxia and Wang, Shang and Miao, Yuqing and Wu, Wenhui},
title = {The role of prolactin/vasoinhibins in cardiovascular diseases},
journal = {Animal Models and Experimental Medicine},
year = {2023},
volume = {6},
number = {2},
pages = {81--91},
doi = {10.1002/ame2.12264}
}
EUVIMED